Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.
PBLS · Parabilis Medicines, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
The closing range uses available history since Jun 10, 2026; less than a full year is stored.
Latest documents
Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.
Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.
Parabolus plans to initiate the global pedestal Phase Three study of Zolucatetide in the first half next year, following an FDA-agreed induction-maintenance regimen; desmoid data showed 62% ORR at 24 months and 72% ORR at 32 weeks.
Parabilis Medicines, Inc. amended its headquarters lease to add 33,525 square feet beginning January 1, 2028, extend the term through December 31, 2037, and provide an option for two additional five-year periods.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
Equibles Research
our published analysis of this companyEquibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| disease control rate (DCR) | 100% | June 22, 2026 data cut | — |
| objective response rate (ORR) | 72.2% | June 22, 2026 data cut | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PBLS
this stock
Parabilis Medicines, Inc.
|
$3.54B | — | — | — | 8.8% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$135.44B | +17.8% | +46.2% | 34.4 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$99.08B | +24.1% | +20.8% | 21.2 | 2.1% |
|
MRNA
Moderna, Inc.
|
$83.68B | +601.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$64.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 16
Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PBLS | -5.9% | +4.3% | — | -0.3% | — |
| SPY | -2.3% | -4.8% | -2.9% | -3.1% | +7.4% |
| vs SPY | -3.6% | +9.1% | — | +2.8% | — |